Mankind Pharma Limited — Important, 28-03-2025: General Updates

Mankind Pharma has received assessment orders from the Income Tax department for the financial years 2014-15 to 2017-18, which include an additional tax demand of ₹183.11 crores due to disallowed expenditures. The company maintains that the demand is legally unsound and believes it has sufficient grounds to challenge the orders, indicating no expected significant impact on its financials or operations. This proactive stance may foster a positive outlook among investors, as Mankind Pharma appears prepared to defend its position and mitigate any potential risks associated with the tax assessment.